Why are you reporting this TALK?
Ipilimumab+Nivolumab
@feedkastVisit
clinical-genitourinary-cancer.com
to learn moreFebruary 4, 2022
3 hr
Channels
DiscoveryCardiologyCOVIDDermatologyEndocrinologyGastroenterologyHematologyHepatologyNephrologyOncologyOphthalmologyPrimary CarePulmonologyRheumatologyUrology
Ipilimumab+Nivolumab